Percutaneous Peritoneal Dialysis Catheter Insertion (PREDICT) (PREDICT)

Prospective Observational Cohort Study on the Outcomes of Percutaneous Inserted PD Catheters

Peritoneal dialysis (PD) is the most frequent modality of home dialysis for patients with kidney failure.

Most PD catheters are placed using a laparoscopic technique. This approach requires the availability of a qualified surgeon, time in the operating theater and general anaesthesia for the patient. Thus, the laparoscopic technique is less suitable for patients with severe heart failure or multimorbidity where general anaesthesia is not possible.

PD catheters can also be inserted using a percutaneous strategy using a modified Seldinger technique. This strategy can be performed bedside under local anaesthesia, by the nephrologist, radiologist, a surgeon, physician assistant or qualified nurse.

The availability of the percutaneous implantation strategy of a PD catheter in a nephrology center may accomodate more patients to receive a PD catheter insertion, including those who have a contraindication to general anaesthesia or need urgent PD.

The PREDICT project aims to increase knowledge and competencies on percutaneous PD catheter insertions by training centers for this technique. By establisching a prospective registry, the outcomes of percutaneously inserted PD catheters, both in experienced and newly trained centers, will be assessed.

Study Overview

• Status: Recruiting
• Conditions: End-stage Kidney Disease
• Intervention / Treatment: Other: Questionnaires

Detailed Description

The population of the PREDICT study are adult patients requiring a peritoneal dialysis catheter insertion. Decision for percutaneous strategy of catheter insertion (versus surgical catheter insertion) is made by the treating physician.

The inclusion criteria for the prospective PREDICT registry are age > 18 years and percutaneous PD catheter insertion between 1 March 2023 and 1 March 1 2026 in participating centers.

Patients can be included 4 weeks before until 12 weeks after PD catheter insertion. The exclusion criteria are the inability to give informed consent and a life expectancy of less than 3 months.

Demographic and clinical data will be collected for all included patients.

• Study Type: Observational
• Enrollment (Estimated): 500

Contacts and Locations

• Study Contact: Name: Karlien François, MD PhD; Phone Number: +324776055; Email: Karlien.Francois@uzbrussel.be

Study Locations

• Belgium
  • Brussels, Belgium, 1090
    • Recruiting
    • Universitair Ziekenhuis Brussel
    • Contact: Karlien François, MD PhD; Email: Karlien.Francois@uzbrussel.be
• Netherlands
  • Utrecht, Netherlands
    • Recruiting
    • UMC Utrecht
    • Contact: Alferso C Abrahams, MD PhD; Email: A.C.Abrahams@umcutrecht.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Adult patients requiring a peritoneal dialysis catheter insertion

Description

Inclusion Criteria:

• Age > 18 years
• Percutaneous PD catheter insertion between March 1st 2023 and March 1st 2026 Patients can be included 4 weeks before until 12 weeks after PD catheter insertion

Exclusion Criteria:

• Inability to provide informed consent
• Life expectancy < 3 months

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Implementation of percutaneus PD catheter insertion technique in dialysis centers	The first co-primary outcome measure assesses the implementation of the percutaneous PD catheter insertion technique in additional dialysis centers.	through study completion, 3 years
Outcomes of percutaneous inserted PD catheters in participating centers	The second co-primary outcome measure assesses the outcomes of percutaneous inserted PD catheters in participating centers: functionality of PD catheters, defined as catheters usable for PD, over 12 months after percutaneous insertion, and taking into account competing events.	Over 12 months after percutaneous insertion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The presence of functioning PD catheter	This secondary outcome measure assesses the presence of functioning PD catheter, defined as catheters usable for PD, over 3 and 6 months after percutaneous PD catheter insertion, censored for competing events.	Over 3 and 6 months after percutaneous PD catheter insertion
Insertion-related complications	This secondary outcome measure assesses insertion-related complications, defined as perforation during or within 48 hours after catheter insertion, bleeding within 7 days of insertion and necessitating blood transfusion and/or invasive intervention to control bleeding, and PD-related infections (i.e. exit-site infection, tunnel infection, peritonitis) within 30 days of insertion.	Perforation during or within 48 hours after catheter insertion, bleeding within 7 days of insertion, and PD-related infections within 30 days of insertion
Mechanical complications	This secondary outcome measure assesses mechanical complications over 3, 6, and 12 months after percutaneous PD catheter insertion. Relevant mechanical complications are defined as flow restrictions, pericatheter leakage, and abdominal pain resulting in an adverse event that is either a lack of PD start, a delay in PD start, an interruption of PD, a permanent termination of PD, emergency room visits, hospital admissions, or need for invasive procedures related to the mechanical catheter complication.	through study completion of the subject, at 1 year or censored for death or kidney replacement modality switch
The rate of PD utilization	This secondary outcome measure assesses the rate of PD utilization, defined as 4 consecutive weeks of PD, after percutaneous PD catheter insertion, censored for competing events.	through study completion of the subject, at 1 year or censored for death or kidney replacement modality switch
Health-related quality of life as assessed by the SF-12 questionnaire	This secondary outcome is assesses health-related quality of life using patient-reported outcome measures (PROMs) at baseline and at 12 months after percutaneous PD catheter insertion, using the validated SF-12 questionnaire.	At baseline and at 12 months after percutaneous PD catheter insertion
Self-assessed health-related quality of life using the EQ5D questionnaire.	This secondary outcome is assesses health-related quality of life in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using the validated EQ5D questionnaire.	At baseline and at 12 months after percutaneous PD catheter insertion
Health care professionals' perspective on the implementation process	This secondary outcome assesses the health care professionals' perspective on the implementation process using the structured Measurement Instrument for Determinants of Innovations. This assessment allows to identify barriers and facilitators of implementation at the level of the percutaneous catheter insertion procedure, at the level of the operator and at the level of the organisation, i.e. the hospital.	At baseline and yearly
Evolution in HD/PD ratio in participating centers throughout the study period	This secondary outcome assesses the evolution in HD/PD ratio in participating centers throughout the study period.	Through study completion, 3 years
Costs of the procedure	The secondary outcome assesses the costs of the procedure.	immediately after the intervention

Collaborators and Investigators

• Sponsor: Universitair Ziekenhuis Brussel
• Collaborators: UMC Utrecht; University Hospital, Antwerp; Imelda Hospital, Bonheiden; Cliniques universitaires Saint-Luc- Université Catholique de Louvain; Leiden University Medical Center; University Medical Centre Ljubljana; Erasme University Hospital; Rijnstate Hospital; Centre Hospitalier Régional de la Citadelle; OLVG; Deventer Ziekenhuis; Isala; Bernhoven Hospital; Bravis Hospital; HagaZiekenhuis; Centro Hospitalar Universitario do Algarve; Medisch Centrum Leeuwarden; Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC); az Glorieux

Study record dates

Study Major Dates

• Study Start (Actual): June 23, 2023
• Primary Completion (Estimated): June 23, 2026
• Study Completion (Estimated): June 23, 2027

Study Registration Dates

• First Submitted: April 28, 2023
• First Submitted That Met QC Criteria: September 29, 2023
• First Posted (Actual): October 4, 2023

Study Record Updates

• Last Update Posted (Actual): October 4, 2023
• Last Update Submitted That Met QC Criteria: September 29, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Urologic Diseases; Disease Attributes; Renal Insufficiency; Renal Insufficiency, Chronic; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Kidney Failure, Chronic
• Other Study ID Numbers: UZB-NEF-2023-PREDICT

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No